Thanks a lot to Lizzy M Brewster for her comments on our article, and for her elaborations and clarifications on risks associated with the use of ACE-inhibitors in patients of African descent. The research quoted shows that in this group, it is necessary to be cautious with blockers of the renin-angiotensin-system, and always balance benefits with risks. At the moment, risks seem to outweigh benefits. However, Brewster mentions that the presented data apply to persons of West and South African ancestry, and, as people of African descent are far from genetically homogenous, it is not obvious how relevant these same data is for treating East Africans, about whom we have far too little knowledge, not only regarding risks and benefits from ACE-inhibitors, but on a variety of medicaments. Moreover, it must be added that treating hypertension in patients with diabetes might require some special considerations regarding kidney disease. Considering these difficulties, like Brewster, I therefore hope that these articles will inspire more research and heightened clinical interest in the field.